How to Store Interleukin: Stability and Handling, Per the Research

Interleukin is not one compound. The term covers a numbered family of cytokine proteins — interleukin-1, interleukin-4, interleukin-6, interleukin-17 and many others — that differ in size, sequence, glycosylation and folding stability. That matters enormously for a storage page, because a stability finding for one interleukin or one interleukin-targeting protein does not automatically transfer to another. Throughout this page, findings that come from a specific interleukin-related molecule are labelled as such, and passages that rest on general protein or lyophilized-formulation science are labelled as general.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing here is a handling protocol, a preparation guide, or a recommendation for any individual.

Why Interleukin Stability Is Harder to Generalise Than Small-Molecule Stability

Small peptides of ten or twenty residues degrade mostly through predictable chemical routes — deamidation, oxidation, hydrolysis. Interleukins are larger folded proteins whose activity depends on tertiary structure, so they can lose function through aggregation, surface adsorption or partial unfolding long before bulk chemical degradation is measurable. Biology itself illustrates how tightly protein turnover is controlled: researchers reported that an SCF(FBXW11) complex targets interleukin-17 receptor A for ubiquitin-proteasome-mediated degradation, a regulated intracellular disposal route for an interleukin receptor (PMID 38672111). That is cellular degradation, not shelf degradation, but it underlines that interleukin-family proteins are built to be short-lived signals rather than durable reagents.

A second reason generalisation fails is that interleukin biology is highly context-dependent. One study reported that interleukin-4 affected microglial autophagic flux, an activity readout that depends on the protein being correctly folded and bioactive rather than merely present by mass (PMID 31089059). Assays that measure concentration and assays that measure activity can therefore disagree after storage stress.

Refrigeration: Lyophilized Versus Reconstituted States

What the lyophilized state changes

General lyophilized-protein science, not interleukin-specific: freeze-drying removes the water that drives hydrolysis and mobility-dependent unfolding, so dried protein powders are conventionally more stable than the same protein in solution at the same temperature. The dried state is not inert, though — residual moisture, excipient choice and the drying method itself shape how the powder behaves.

Interleukin-relevant evidence for that last point exists. Researchers compared spray-dried and spray-freeze-dried powder formulations of an anti-interleukin-4Rα antibody intended for pulmonary delivery, reporting that the two drying processes produced different powder characteristics for the same biologic (PMID 35879500). The molecule there was an antibody against an interleukin receptor rather than an interleukin itself, so the finding speaks to process-dependent powder behaviour in the interleukin space, not to interleukin protein powders directly.

What solution storage looks like over long periods

The most striking refrigerated-solution datapoint in this area concerns anakinra, a recombinant interleukin-1 receptor antagonist. An analytical study reported that Kineret protein solution survived ten years, with the stored material assessed by pharmaceutical and biomedical analysis methods (PMID 30121556). That is a single formulated, preserved, commercially manufactured product examined in a laboratory setting — it describes what one interleukin-1 receptor antagonist solution did, and it is not a statement about interleukin proteins generally, about research-grade material, or about what any product label permits.

Shelf Life and Expiry: What the Studies Report

Expiry dating on a manufactured biologic is a regulatory construct — the period a manufacturer has supported with its own stability programme — rather than a measurement of the moment a protein stops working. Independent long-term analyses sometimes find material still measurable well past that window, which is what makes the anakinra report notable: the study reported that the interleukin-1 receptor antagonist solution remained analysable after ten years of storage (PMID 30121556). Researchers publishing that kind of result are describing laboratory persistence of a molecule, not endorsing use of expired material, and sterility, container closure integrity and preservative performance are separate questions that such an analysis does not settle.

For research-grade interleukins, no single shelf-life figure covers the family. Vendors of research chemicals typically issue their own certificate-of-analysis stability statements per lot, and those statements are manufacturer data rather than peer-reviewed findings. Where a page like this cannot point to a published interleukin-specific number, the honest answer is that the number does not exist in the literature cited here.

Freezing and Freeze–Thaw Cycling

Freezing is the default long-term strategy for protein reagents, but the damaging step is usually the transition, not the hold. Ice formation concentrates solutes, shifts pH in some buffer systems, and creates ice–water interfaces where proteins can unfold and aggregate; each additional cycle repeats that stress.

The most directly relevant published dataset examined serum rather than purified reagent. A 2024 analysis performed quantitative and qualitative assessment of stability for 16 serum immunoregulators over 50 freeze–thaw cycles, and reported that the immunoregulators did not behave uniformly across that cycling (PMID 38682460). The practical lesson researchers drew from that design is analyte-specific: an interleukin measured in one matrix may tolerate cycling differently from its neighbour on the same panel, so blanket "cytokines survive freeze–thaw" claims are not supportable.

Matrix effects extend beyond serum. A review of sample processing and stability for urine biomarker studies described how collection, processing delay and storage conditions influence measured biomarker concentrations (PMID 34414423). That work is general analytical guidance rather than interleukin-specific stability data, but it is the reason cytokine results are usually reported alongside a described handling protocol.

Interleukin measurements are also used as stability readouts for other analytes, which is a separate use of the word. In one study, researchers reported that the stability of SARS-CoV-2-encoded proteins and their antibody levels correlated with interleukin 6 in COVID-19 patients (PMID 35582921). There, interleukin-6 was the biological variable being correlated, not a stored reagent — a distinction worth keeping straight when searching the literature for "interleukin stability".

Room Temperature and Travel

General protein-formulation science, not interleukin-specific: ambient excursions matter more for solutions than for dried powders, because water mobility is what permits both chemical degradation and conformational change. Excursion tolerance is a property of a specific formulation — its buffer, pH, surfactant, sugar and container — rather than of the protein name on the label, which is why two products containing related molecules can carry different excursion allowances.

Dried-powder work in the interleukin space supports the same point from a different angle: the comparison of spray-dried and spray-freeze-dried anti-interleukin-4Rα antibody powders showed that formulation and process choices, not the molecule alone, defined the resulting powder's properties (PMID 35879500). For biofluid samples in transit, the urine biomarker review described processing and storage variables as determinants of what an assay eventually measures (PMID 34414423).

Degradation Signs and How Studies Detect Them

Physical observations

General protein science: visible cues discussed in protein formulation literature include haze or opalescence in a previously clear solution, visible particulates, colour change, a collapsed or shrunken lyophilized cake, and a cake that dissolves more slowly than expected. None of these is definitive, and their absence does not establish potency.

Analytical detection

Laboratories rely on instruments rather than eyes. The ten-year anakinra assessment used pharmaceutical and biomedical analytical methods to characterise the stored interleukin-1 receptor antagonist solution (PMID 30121556), and the freeze–thaw work applied both quantitative and qualitative analysis across the 50-cycle series for its 16 serum immunoregulators (PMID 38682460). Function-based readouts add another layer: the study that reported interleukin-4 affecting microglial autophagic flux measured a biological response rather than protein mass (PMID 31089059).

Biological Degradation Is Not Shelf Degradation

Searches for "interleukin degradation" surface a large body of cell-biology work that has nothing to do with storage. Researchers reported that lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells (PMID 24292625), and a 2025 study reported that succinate drives gut inflammation by promoting FOXP3 degradation through a molecular switch (PMID 40457062). Both describe targeted intracellular protein destruction in immune settings.

The same distinction applies to inflammation research more broadly: one study reported that targeting phenylpyruvate restrained excessive NLRP3 inflammasome activation and pathological inflammation in diabetic wound healing (PMID 37480849), another reported that sodium butyrate abolished the degradation of type II collagen in human chondrocytes (PMID 29710527), and a 2025 report described HNRNPA1 promoting TRIM37 mRNA stability and mediating TRAF6 ubiquitination in osteoarthritis (PMID 41014769). "Stability" in those titles refers to molecular turnover inside living tissue, not to how a vial behaves in a refrigerator.

What the Evidence Base Does and Does Not Cover

• Compound-specific: a single interleukin-1 receptor antagonist product solution was reported intact after ten years of storage (PMID 30121556).
• Family-relevant but process-focused: drying method shaped powder properties for an anti-interleukin-4Rα antibody (PMID 35879500).
• Matrix-level: 16 serum immunoregulators were tracked over 50 freeze–thaw cycles (PMID 38682460), and biofluid processing variables were reviewed for urine biomarkers (PMID 34414423).
• Not covered here: no published storage temperature, expiry interval or reconstituted hold time for research-grade interleukin preparations appears in the sources cited on this page, and none is invented to fill the gap.

Readers comparing this against other compounds may find the broader background at /learn/interleukin/ and the cross-compound overview at /guides/how-to-store-peptides/ useful for context. Again, this page is educational only and is not medical advice; a licensed physician is the appropriate source for any individual decision.

References

• Kineret protein solution survives ten years (Journal of Pharmaceutical and Biomedical Analysis, 2018)
• Quantitative and qualitative analysis of stability for 16 serum immunoregulators over 50 freeze-thaw cycles (American Journal of Human Biology, 2024)
• Spray-Dried and Spray-Freeze-Dried Powder Formulations of an Anti-Interleukin-4Rα Antibody for Pulmonary Delivery (Pharmaceutical Research, 2022)
• Sample Processing and Stability for Urine Biomarker Studies (The Journal of Applied Laboratory Medicine, 2021)
• Stability of SARS-CoV-2-Encoded Proteins and Their Antibody Levels Correlate with Interleukin 6 in COVID-19 Patients (mSystems, 2022)
• SCF(FBXW11) Complex Targets Interleukin-17 Receptor A for Ubiquitin-Proteasome-Mediated Degradation (Biomedicines, 2024)
• Interleukin-4 affects microglial autophagic flux (Neural Regeneration Research, 2019)
• Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells (Science, 2014)
• Succinate drives gut inflammation by promoting FOXP3 degradation through a molecular switch (Nature Immunology, 2025)
• Targeting phenylpyruvate restrains excessive NLRP3 inflammasome activation and pathological inflammation in diabetic wound healing (Cell Reports Medicine, 2023)
• Sodium butyrate abolishes the degradation of type II collagen in human chondrocytes (Biomedicine & Pharmacotherapy, 2018)
• HNRNPA1 promotes TRIM37 mRNA stability and mediates TRAF6 ubiquitination to alleviate osteoarthritis (International Immunopharmacology, 2025)